Editors:
- Elucidates the benefits and pitfalls of current clinic FDG PET
- Enriches understanding of moving radiopharmaceuticals from the workbench to the clinic
- Provides translational research for clinical discussions about pathway directed systems imaging which correlates with genomic and proteomic expressions
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (14 chapters)
-
Front Matter
-
Engineering and Instrumentation Aspect
-
Front Matter
-
-
Clinical Aspect
-
Front Matter
-
About this book
This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed.
Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agentshave potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome.
This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.
Editors and Affiliations
-
School of Medicine, Yokohama City University, Yokohama, Japan
Tomio Inoue
-
Vyripharm Biopharmaceuticals, University of Texas Health Science Center, Houston, USA
David Yang
-
Renji Hospital / Department of Nuclear Medicine, Shanghai Jiao Tong University, Shanghai, China
Gang Huang
About the editors
Dr. Tomio Inoue
President, Yokohama City University Medical Center
Dr. David J. Yang
Professor and Section Chief, Radiotheranostic Section,
Department of Cancer System Imaging,
Division of Diagnostic Imaging,
MD Anderson Cancer Center,
Consultant and Professor at The University of Tennessee Health Science Center,
Vice-president for Vyripharm Biopharmaceuticals
Dr. Gang Huang
Chairman, Institute of Nuclear Medicine,
Shanghai JiaoTong University School of Medicine
Bibliographic Information
Book Title: Personalized Pathway-Activated Systems Imaging in Oncology
Book Subtitle: Principal and Instrumentation
Editors: Tomio Inoue, David Yang, Gang Huang
DOI: https://doi.org/10.1007/978-981-10-3349-0
Publisher: Springer Singapore
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Nature Singapore Pte Ltd. 2017
Hardcover ISBN: 978-981-10-3348-3Published: 10 March 2017
Softcover ISBN: 978-981-10-9850-5Published: 08 August 2018
eBook ISBN: 978-981-10-3349-0Published: 01 March 2017
Edition Number: 1
Number of Pages: XII, 243
Number of Illustrations: 41 b/w illustrations, 71 illustrations in colour
Topics: Nuclear Medicine, Oncology